key: cord-0794259-vqet6ept
authors: van Merendonk, Lisanne N; Leeuwerik, Anke F; den Brok, Monique W J; Hekking, Pieter-Paul W; Korevaar, Daniel A; Jacobs, Christian J; Bet, Pierre M
title: Peripheral infiltration of remdesivir in 3 patients with COVID-19: Case series and discussion
date: 2021-05-05
journal: Am J Health Syst Pharm
DOI: 10.1093/ajhp/zxab197
sha: 689f25649842289f643858b3bf5ffdf014e1927d
doc_id: 794259
cord_uid: vqet6ept

PURPOSE: The coronavirus disease 2019 (COVID-19) pandemic resulted in accelerated market access to remdesivir worldwide. Therefore, data about complications experienced during use of the drug are limited. This is the first published case series (1 case report exists) to describe remdesivir infiltration in 3 patients with COVID-19. SUMMARY: In the first case, a 91-year-old woman experienced remdesivir infiltration resulting in edema, hematoma at the area of infiltration; on palpation, the affected area felt cooler than the surrounding areas. Swelling was still present after 6 weeks. In the second case, remdesivir infiltration occurred in a 72-year-old male, resulting in edema, hematoma, and pain at the area of infiltration. The hematoma lasted for 7 days. The third case concerned a 67-year-old woman, in whom remdesivir infiltration led to edema and a small hematoma. The hematoma regressed to a negligible size within 3 days. However, a week after infiltration, redness had reappeared. In 2 cases, the patient was immediately treated with hyaluronidase injections, but no specific treatments were provided in the other case. CONCLUSION: Based on the product information provided by remdesivir’s manufacturer, we believe symptoms and signs observed in the 3 cases may have resulted from the low pH (~4) of the nonbuffered remdesivir solution, although the patients were not formally assessed for caustic injury. Previous experience with other noncytotoxic medications suggests that infusion-specific factors (eg, volume of leaked fluid) and patient-specific factors (eg, advanced age) may have a role in the outcome of remdesivir infiltration. The possibility of symptoms caused by cyclodextrins in the formulation or by intrinsic toxicity of remdesivir warrants exploration.

M a n u s c r i p t Am J Health-Syst Pharm. 2021;78(x):xxx-xxx In hospitalized patients, unintentional leakage of an intravenously administrated agent into the surrounding subcutaneous tissue occurs with an incidence ranging from 0.1% to 6%. 1 This leakage is defined as extravasation if the administered agent has the potential to initiate severe tissue damage. Mostly, this potential to harm the surrounding tissue is based on the distinguishing between vesicant and nonvesicant agents. 1, 2 According to this definition, leakage of a nonvesicant solution into the surrounding tissue is defined as infiltration. Leaked agents can cause tissue injury depending on the characteristics of the agent, the physiochemical properties of the solution, the infiltrated volume, and patient characteristics. 1 The mechanisms of tissue damage caused by subcutaneous leaked noncytotoxic agents are explained in Table 1 . 1, 3, 4 Treatment of infiltration is based on the underlying mechanism of tissue damage and is drug specific. However, nonpharmacological general supportive care must be applied first in the event of subcutaneous leakage of any infused agent (Box 1). 4 Based on the possible mechanisms of damage that can be caused by an infiltrated medication, additional interventions may be required (Table 1) . Pharmacological and nonpharmacological postinfiltration interventions can roughly be divided into 2 groups: "disperse and dilute" and "concentrate and condensate." 5 The disperse-and-dilute method is mainly preferred when the potential for tissue damage is related to the concentration of the solution. When the infiltrated solution will be diffused into a larger area, it is diluted and the harmfulness decreases. For instance, this applies to solutions at extremities of pH. The pH will restore to a more neutral acidity after dilution and therefore be less harmful. The use of warm compresses in the disperse-and-dilute method will lead to vasodilation and A c c e p t e d M a n u s c r i p t subsequently to enhanced absorption. Besides warm compresses to induce vasodilatation, hyaluronidase injections can be used to break down tissue to increase the available area for absorption. Furthermore, flushing with 0.9% sodium chloride injection can also be used to disperse and dilute. Flushing can be applied when the catheter is not removed. The concentrate-and-condensate method is preferred if subcutaneously leaked agents have the potential to cause highly severe tissue injury. Dispersing these agents may lead to a larger area of tissue injury. This method is applicable to all vesicant and irritating drugs except for vinca alkaloids and vasopressors. In order to keep the drug in the area of infiltration, cold compresses can be used to achieve vasoconstriction and to lower the absorption. Therefore, inflammation or necrosis induced by the agent may be reduced. Furthermore, specific antidotes to counteract local pharmacological effects can be used depending on the infiltrated drug (eg, phentolamine for vasoconstrictors). 5 Remdesivir (Veklury, Gilead Sciences) is an antiviral drug that is currently used on a major scale worldwide for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is a prodrug that is intracellularly metabolized into the active metabolite GS-443902 and inhibits the replication of viral RNA. 6, 7 In the United States, remdesivir was approved by the Food and Drug Administration (FDA) on May 1, 2020, through an emergency use authorization (EUA); in the European Union, the drug received a conditional marketing authorization by the European Medicines Agency (EMA) on June 3, 2020. 8, 9 Therefore, data about the effects and adverse events of remdesivir are still relatively limited. Remdesivir's product label reports infiltration as an adverse event during EUA-authorized use without specifying corresponding symptoms, whereas infiltration or extravasation was not reported as a common or serious adverse event in phase 3 clinical trials. 10, 11 Therefore, the manufacturer does not provide instructions regarding follow-up or A c c e p t e d M a n u s c r i p t treatment. 7, 12 Based on the product information provided by the manufacturer, remdesivir is a nonvesicant agent. To our knowledge, there is 1 prior published case report describing painful blisters, hemorrhage, and localized edema following remdesivir extravasation. 13 In this case series, we describe the clinical manifestations of remdesivir infiltration in 3 hospitalized patients with COVID-19.

All 3 patients were admitted to our teaching hospital, Amsterdam University Medical Center. Basic facts of the 3 cases are summarized in Table 2 . The hospital pharmacist was consulted, and general care was carried out according to the recommendations in Table 2 . An attempt to aspirate the ostensibly leaked remdesivir solution through the catheter with an empty syringe did not succeed. hours after the infiltration, the area was still swollen, the area continued to feel cooler than the surrounding tissue, and a hematoma appeared (Figure 1 ). The affected area of infiltration was not expanding, nor did the patient report any pain. By the seventh day, the hematoma and swelling were decreasing in size. The temperature of the area, assessed by A c c e p t e d M a n u s c r i p t palpation, now felt normal compared to the surrounding tissue, and the patient had not experienced any pain (Figure 1 ). At a follow-up visit after 4 weeks, the hematoma was no longer visible. The swelling at the area of infiltration had further decreased but was still visible (Figure 2) . The patient had not reported any pain. After 6 weeks the area of infiltration was still slightly swollen and had not decreased in size. No other signs could be observed, nor did the patient report discomfort or pain. Remdesivir was administrated intravenously via peripheral access in the right hand in the same dosages as described for case 1. On the second day of remdesivir treatment, the patient noticed swelling and a painful sensation around the site of administration. No histology was performed. Remdesivir infusion was discontinued, but the infiltrated volume was not documented by the nursing staff and therefore was not precisely known. The area of infiltration was marked. However, no other general care measures (eg, aspiration of the leaked fluid and elevation of the affected body part; see Box 1) were performed by the clinical staff due to unfamiliarity with recommended interventions. The hospital pharmacist A c c e p t e d M a n u s c r i p t was consulted, and it was decided to administer local hyaluronidase injections. A few hours after the infiltration, swelling and a small hematoma were visible. By the seventh day, the swelling had diminished and the hematoma had decreased substantially (Figure 3 ). At a follow-up visit after 4 weeks, there were no more visible signs, nor did the patient report any symptoms. A remdesivir infusion was administrated intravenously via peripheral access in the right wrist in the same dosages as described for case 1. On the second day, the patient noticed an area of severe tenderness on her dorsoradial right wrist around the infusion site.

The nursing staff reported a tender and erythematous swelling at the area of infiltration of approximately 3 cm in diameter after administration of the infusion. No histology was performed on the affected area. The area of infiltration was marked, and the nursing staff attempted to aspirate the leaked remdesivir solution. Considering that the observed effects occurred after the end of the infusion, it was possible that the administered dose, containing 100 mg of remdesivir, fully leaked into the surrounding tissue, but the exact A c c e p t e d M a n u s c r i p t amount was unclear. Furthermore, infiltration of 0.9% sodium chloride injection could not be ruled out. The hospital pharmacist was consulted and advised local administration of hyaluronidase. However, hyaluronidase was not available at the department, and observation was initiated in consultation with a plastic surgeon. In addition, general care interventions ( Table 2 ) were performed. The following day, the marked infiltration area was still swollen and red (Figure 4 ). These signs decreased by the second day after the infiltration, with only minimal discomfort reported by the patient, and completely resolved by the third day. However, a week after the infiltration, a rust-colored redness had reappeared and, on palpation, the affected area felt cooler than the surrounding tissue, without signs of edema or symptoms of pain ( Figure 5 ). At a follow-up visit after 4 weeks, there were no visible signs of redness or a skin temperature difference. The patient did not report experiencing any symptoms.

All patients provided written informed consent for us to publish the data and photos included in this report.

Only 1 prior report of remdesivir infiltration has been published. 13 Infiltration of remdesivir at the infusion site has been reported previously as an adverse event. 7, 12 However, the clinical impact of the infiltration in clinical studies was not described.

Therefore, treatment advice in our hospital was based on the known pharmacological properties of remdesivir, patient characteristics, and mechanism of tissue damage of noncytotoxic agents ( Table 1 ). The excipients present in the remdesivir formulation are sulfobutylether-β-cyclodextrin (SBECD), hydrochloric acid, sodium hydroxide, and water for injection. 6 SBECD is added to the formulation to increase solubility and stability by accommodating remdesivir molecules within the cavity of SBECD. 14 However, the effect of A c c e p t e d M a n u s c r i p t SBECD on the subcutaneous tissue is unknown. Furthermore, the pH of the nonbuffered diluted infusion solution is 4 (information obtained from the manufacturer). Infiltration of solutions with a low pH (<5) can lead to vasoconstriction and precipitation of proteins and, finally, severe tissue injury (Table 1) . 15 Remdesivir was administrated in our hospital through a 100-mL infusion at a rate of 200 mL/h. Depending on the infiltrated volume, mechanistic damage could also result in tissue injury. In 2 of the described cases the infiltration was noticed after the end of the infusion. Therefore, a high amount of infiltrated volume may have been possible, and mechanistic damage was considered. Furthermore, damage related to the formulation's osmolality was not expected due to the osmolality being 320 mOsm/kg, according to information obtained from the manufacturer. That osmolality does not exceed the threshold for harmful hyperosmolality (Table 1) However, infiltrations of other antiviral nucleotide and nucleoside analogues have been reported previously. 16, 17 The injuries described in those reports (tissue necrosis and bullae formation) were believed to be caused by the alkalinity of the acyclovir and ganciclovir solution (pH of 11). 16, 17 Therefore, the observed injuries are unlikely to represent a class effect, but rather are likely a consequence of the pH of the formulation. Acidic pH is considered to be a risk factor for tissue injury. 18, 19 For instance, infiltration of amiodarone, with an acidic pH (3.5-4.5) , was reported to result in severe pain, erythema, and warmth. 20 Furthermore, reported cases of infiltration of vancomycin (pH of 2.5-4.0) involved an ischemic lesion or vesicle redness and swelling. 21, 22 Therefore, signs and symptoms observed in our cases may have been a result of the acidic pH of the solution, although causality could not be established.

A c c e p t e d M a n u s c r i p t

The effect of SBECD on the severity of infiltration could not be defined, as it was unknown whether remdesivir would be released from SBECD in the subcutaneous tissue similarly to the drug's dilution in plasma. 23 Furthermore, there is no published information on the pharmacokinetics of SBECD in subcutaneous tissue or infiltration of other agents formulated with SBECD. 24 Other factors that may have affected the occurrence of the infiltration were infusion-specific factors and patient-specific factors. 1 With regard to the infusion-specific factors, the high infiltration volume (possibly up to 100 mL) and the high infusion rate (200 mL/h) were risk factors. In addition, catheter location in the dorsum of a hand (case 2) and the need for catheter readjustments (case 1) could have increased the risk of infiltration. 1 Patient-specific factors that might have influenced the clinical manifestations were patient age and condition (in case 1) 1 ; however, the relationship of these risk factors to the case remains unproven.

Hyaluronidase injections were the recommended intervention for the remdesivir infiltration cases in our hospital. Hyaluronidase has been proven to be effective in treatment of extravasation of hyperosmolar drugs. 4 Its mechanism of action is due to hydrolysis of the enzyme hyaluronic acid in connective tissue; this results in degradation of the interstitial barrier, facilitating an increase in distribution and absorption of the infiltrated drug. 1, 25 Therefore, the duration of symptoms and signs (eg, swelling) is limited. 1 Moreover, some case reports describe that symptoms after infiltration of acidic or alkaline drugs resolve quickly after hyaluronidase administration. 1, 20 Therefore, hyaluronidase could in theory be an option after infiltration of acidic drugs when the goal is to disperse and dilute the infiltrated drug. 25 The acidic pH of the remdesivir solution and the possibility of high infiltrated volumes in our cases were considered the most important factors on which to base the M a n u s c r i p t treatment strategy. Therefore, administration of hyaluronidase injections was recommended for quick distribution and absorption. Some observed signs in our cases appeared to resolve after these injections, although causality remains unclear. In the previously published case of remdesivir infiltration involved blisters, hemorrhage, and localized edema. 13 Treatment consisted of oral prednisolone to suppress inflammation.

However, local or systemic administration of corticosteroids has not been proven to be effective for treatment of infiltration or extravasation. 25 In future, other treatment strategies for remdesivir infiltration-for instance, flushing with 0.9% sodium chloride injection to distribute and dilute the infiltrated drug or use of warm compresses and other supportive care, as recommended for acidic drugs (Table 1 ) 1 -could also be considered

We have presented 3 cases of a remdesivir infiltration and possible mechanisms of tissue injury after infiltration. Clinical effects observed in our cases were swelling (for up to 6 weeks), hematoma or redness, severe pain, and cooler temperature in the affected area compared to the surrounding tissue. We identified the low pH of the solution as a possible cause of the observed signs, and therefore administration of hyaluronidase injections was recommended in addition to general care interventions (eg, elevation of the affected body part). The presence of any intrinsic toxicity of remdesivir on tissue and the role of cyclodextrins in the formulation remain to be studied. Some effects, such as swelling, pain, and hematoma, appeared to decrease after hyaluronidase administration, although a relationship cannot be established.

The authors have declared no potential conflicts of interest. M a n u s c r i p t

 Observed symptoms and signs following remdesivir infiltration (edema, hematoma, decreased temperature by palpation, and pain) decreased in a few days.

 The acidic pH of the remdesivir solution may have influenced the signs and symptoms observed in the 3 cases of remdesivir infiltration reported here.

 Reappearance of signs a week after remdesivir infiltration occurred in 1 case not involving treatment with hyaluronidase injections. M a n u s c r i p t 

Management of extravasation injuries: a focused evaluation of noncytotoxic medications

IV therapy: recognizing the differences between infiltration and extravasation

Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines

Extravasation of noncytotoxic drugs

Ter Horst P. An update on extravasation: basic knowledge for clinical pharmacists

Summary of product characteristics

Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects

FDA approves first Treatment for COVID-19 Published

Remdesivir for the treatment of Covid-19 -final report

Remdesivir for 5 or 10 Days in patients with severe Covid-19

FDA Adverse Event Reporting System Freedom of Information Act (FOIA) detailed report: remdesivir

Painful blisters of left hand following extravasation of remdesivir infusion in COVID-19

Mechanisms of drug release from cyclodextrin complexes

Infiltration and extravasation: Update on prevention and management

Tissue necrosis following extravasation of acyclovir in an adolescent: a case report

Ganciclovir-induced bullae formation secondary to extravasation in a patient being treated for cytomegalovirus retinitis

Experimental infusion phlebitis: tolerance pH of peripheral vein

A eeview of pH and osmolarity

Management of amiodarone extravasation with intradermal hyaluronidase

Severe local vancomycin induced skin necrosis

Bullous dermatosis associated with vancomycin extravasation

Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug/cyclodextrin complexes

Background Review for cyclodextrins used as excipients

Extravasation of noncytotoxic drugs: a review of the literature

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t  Attempt to aspirate the leaked solution with an empty syringe through the catheter. Remove the needle. Mark the area of infiltration and take a picture. Note the hour. Elevate the affected body part (for 48 hours) and immobilize it. Perform additional care based on the characteristics of the infiltrated agent (Table 1) . Monitor the patient until the symptoms disappear.